New agent, eribulin, derived from marine sponge, increases survival among women with metastatic breast cancer

Share :
Published: 11 Jun 2010
Views: 9863
Prof Christopher Twelves - Leeds Institute of Molecular Medicine and St. James's Institute of Oncology, Leeds, UK
Prof Christopher Twelves, speaking at the 2010 ASCO conference: A Phase III randomised trial finds that a new chemotherapy agent, eribulin mesylate, extends median overall survival by 2.5 months among women with locally recurrent or metastatic breast cancer who had already been heavily treated with conventional therapies.

Click here to see Prof. Twelves speaking to ecancertv about the survival benefits of eribulin.